TD Cowen Begins Coverage on Inventiva (NASDAQ:IVA)

Stock analysts at TD Cowen initiated coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. TD Cowen’s price target would indicate a potential upside of 252.11% from the company’s current price.

IVA has been the topic of a number of other research reports. Stifel Nicolaus cut their price target on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. UBS Group began coverage on shares of Inventiva in a report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Inventiva in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Inventiva presently has an average rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Trading Up 3.6 %

Shares of NASDAQ:IVA opened at $2.84 on Friday. The firm’s fifty day moving average is $2.33 and its 200-day moving average is $2.36. Inventiva has a 52 week low of $1.53 and a 52 week high of $4.50.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.